Comparison of silicate-substituted calcium phosphate (actifuse) with recombinant human bone morphogenetic protein-2 (Infuse) in posterolateral instrumented lumbar fusion

Licina, Paul, Coughlan, Marc, Johnston, Emma, & Pearcy, Mark J. (2015) Comparison of silicate-substituted calcium phosphate (actifuse) with recombinant human bone morphogenetic protein-2 (Infuse) in posterolateral instrumented lumbar fusion. Evidence-Based Spine-Care Journal, 5(6), pp. 471-478.


View at publisher (open access)


Study Design

  • This was a randomised controlled trial in patients with degenerative disc disease (DDD) who underwent instrumented posterolateral lumbar fusion (PLF) surgery.


  • The aim of this study was to assess the efficacy of the bone grafting substitute, silicate-substituted calcium phosphate (SiCaP) compared with bone morphogenetic protein (rhBMP-2) and to evaluate clinical outcomes over a period of two years.


  • Patients undergoing PLF surgery for DDD at a single centre were recruited and randomised to one of two groups; SiCaP (n=9) or rhBMP-2 (n=10). One patient withdrew prior to randomisation and another from the rhBMP-2 group after randomisation. The radiological and clinical outcomes were examined and compared. Fusion was assessed at 12 months with computed tomography (CT) and plain radiographs. Clinical outcomes were evaluated by recording measures of pain, quality of life, disability and neurological status from six weeks to two years postoperatively.


  • In the SiCaP and rhBMP-2 groups, fusion was observed in 9/9 and 8/9 patients respectively. Pain and disability scores were reduced and quality of life increased in both groups. Leg pain, disability and satisfaction scores were similar between the groups at each postoperative time point, however, back pain was less at six weeks and quality of life was higher at six months in the SiCaP group than the rhBMP-2 group.


  • SiCaP and rhBMP-2 were comparable in terms of achieving successful bone growth and fusion. Both groups similarly alleviated pain and improved quality of life, neurological, satisfaction and return to work outcomes following PLF surgery.

Impact and interest:

Citation counts are sourced monthly from Scopus and Web of Science® citation databases.

These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.

Citations counts from the Google Scholar™ indexing service can be viewed at the linked Google Scholar™ search.

Full-text downloads:

8 since deposited on 31 Aug 2015
5 in the past twelve months

Full-text downloads displays the total number of times this work’s files (e.g., a PDF) have been downloaded from QUT ePrints as well as the number of downloads in the previous 365 days. The count includes downloads for all files if a work has more than one.

ID Code: 87012
Item Type: Journal Article
Refereed: Yes
Keywords: lumbar fusion, bone graft substitute, actifuse, bone morphogenetic protein, infuse
DOI: 10.1055/s-0035-1566230
ISSN: 1663-7976
Subjects: Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > CLINICAL SCIENCES (110300) > Orthopaedics (110314)
Divisions: Current > Schools > School of Chemistry, Physics & Mechanical Engineering
Current > Institutes > Institute of Health and Biomedical Innovation
Current > QUT Faculties and Divisions > Science & Engineering Faculty
Copyright Owner: © 2015 Georg Thieme Verlag KG
Stuttgart · New York
Deposited On: 31 Aug 2015 03:49
Last Modified: 02 Sep 2016 08:40

Export: EndNote | Dublin Core | BibTeX

Repository Staff Only: item control page